Rejoin Medical Secures ￥100 Million in Series B Funding

(VCBeat) Aug. 2, 2021 -- Recently, Rejoin Medical, a leader in sports medicine, announced the completion of a Series B financing of hundreds of millions. This round was led by Vertex Ventures, with participation from Addor Capital, and the existing investor Simiao Capital. It is reported that the funds raised will be used to develop new products and basic materials, build domestic and foreign sales teams, and carry out professional marketing activities.

Rejoin Medical is an orthopedic device company of minimally invasive surgery with sports medicine as its core. With more than 50 independent patents, Rejoin Medical is committed to providing more simple and reliable overall solutions for doctors and patients in the field of sports medicine and surgeon-designed minimally invasive technologies. At present, the company has successfully built an ecosystem that includes independent basic material research and development, product development and industrial production. At the same time, the company has obtained 6 Class III registration certificates and 5 Class II registration certificates of NMPA, and 18 kinds of products have obtained the CE certificates. The products have been sold to dozens of countries around the world, covering nearly 1,000 hospitals.

Mr. Xu Shengjun, the founder of Rejoin Medical, has more than 20 years of experience in the field of orthopedics. He founded Rejoin Medical in 2010 and has accumulated rich experience in the production of orthopedics products and a deep insight into the global sports medicine field during the cooperation with internationally renowned orthopedic device manufacturers such as Zimmer Biomet.

In 2021, Rejoin Medical will obtain Class III or Class II registration certificates for a number of series products such as all-suture anchors. At the same time, the company will make further efforts in overseas markets by gradually establishing a global research and development system.

Vertex Ventures is a global network of venture capital funds. The operator-investors manage portfolios in China, the U.S., Israel, India, and Southeast Asia. 

Vertex Ventures China, founded in 2008, has offices in Beijing, Shanghai, and Shenzhen. It is currently managing both Dollar and RMB funds, with assets under management of over ¥10 billion. Vertex Ventures China invests in high-growth innovative start-ups across mainland China, covering the fields of deep tech, new digital economy, and healthcare.

Addor Capital offers investment services by financing early-stage ventures and holding securities of other companies. It invests in a number of strategic emerging industries such as clean technology, health industry, new materials, advanced manufacturing, smart transportation, consumer services, cultural industry, and TMT.

By June 2021, Addor Capital had invested in 1,021 start-ups, helping 211 of which to land in domestic and foreign capital markets with AUM of 111.1 billion yuan.